8-chloro-4,5,6,11-tetrahydro-2H-pyrazolo[4',3':6,7]cyclohepta[b]indole | 1356957-80-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 8-chloro-4,5,6,11-tetrahydro-2H-pyrazolo[4',3':6,7]cyclohepta[b]indole
• 英文别名: 13-Chloro-3,4,17-triazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),2(6),4,11(16),12,14-hexaene；13-chloro-3,4,17-triazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),2(6),4,11(16),12,14-hexaene
• CAS: 1356957-80-6；746666-06-8
• 化学式: C₁₄H₁₂ClN₃
• 分子量: 257.722
• InChiKey: QTMIIGKTTKFZKT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  44.5
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-chloro-7-(hydroxymethylene)-7,8,9,10-tetrahydrocyclohepta[b]indol-6(5H)-one 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 5.0h， 以60%的产率得到8-chloro-4,5,6,11-tetrahydro-2H-pyrazolo[4',3':6,7]cyclohepta[b]indole
  参考文献：
  名称：

  Synthesis, antimicrobial, antimycobacterial and structure–activity relationship of substituted pyrazolo-, isoxazolo-, pyrimido- and mercaptopyrimidocyclohepta[b]indoles

  摘要：

  A new class of heterocycles, specifically substituted pyrazolo-, isoxazolo- and pyrimidocyclohepta[b]indoles, has been prepared by condensation of substituted 7-(hydroxymethylene)-7,8,9,10-tetrahydrocyclohepta[b]indol-6(5H)-ones with hydrazine hydrate, hydroxylamine hydrochloride, phenylhydrazine, urea and thiourea, respectively. The structures of the compounds were established by IR, H-1 NMR, C-13 NMR, mass spectral analysis, X-ray diffraction, and the compounds have been screened for in vitro antimicrobial and antimycobacterial against Mycobacterium tuberculosis H37Rv (MTB). Among the compounds screened, five substances were found to have an MIC of 3.12 mu g/ml or greater against MTB. Structure-activity relationship (SAR) analyses and in silico drug relevant properties (HBD, HBA, PSA, c Log P, M.wt) confirmed that the compounds are potential lead compounds for future drug discovery studies. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.10.046

文献信息

• Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
  申请人：Vanotti Ermes

  公开号：US20060264493A1

  公开（公告）日：2006-11-23

  The present invention provides a method for treating diseases caused by and/or associated with an altered protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a tetracyclic pyrazole. The invention also provides specific tetracyclic pyrazole derivatives, useful intermediates, a library comprising at least two of them, a process for their preparation and the pharmaceutical compositions containing them, which are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, viral infections, autoimmune diseases and neurodegenerative disorders.

  本发明提供了一种治疗由改变的蛋白激酶活性引起和/或相关的疾病的方法，包括向需要治疗的哺乳动物中给予有效量的四环吡唑。本发明还提供了特定的四环吡唑衍生物、有用的中间体、包含至少两个四环吡唑衍生物的库、它们的制备方法以及含有它们的药物组合物，这些组合物对于治疗由改变的蛋白激酶活性引起和/或相关的疾病，如癌症、细胞增殖性疾病、病毒感染、自身免疫性疾病和神经退行性疾病非常有用。
• Indole Derivative and Use for Treatment of Cancer
  申请人：Nishikimi Yuji

  公开号：US20070254877A1

  公开（公告）日：2007-11-01

  The present invention relates to a compound represented by the formula wherein A is a benzene ring optionally having substituents, R 1 , R 2a and R 3 are each a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, R 1 and R 2a may form a ring via X, when R 1 and R 2a form a ring via X, R 1 and R 2a are each a bond or a divalent C 1-5 acyclic hydrocarbon group optionally having substituents, and X is a bond, an oxygen atom, an optionally oxidized sulfur atom or an imino group optionally having a substituent, provided that R 1 , R 2a and X are not bonds at the same time, or a salt thereof, and an agent for inhibiting kinase (phosphorylation enzyme), which contains this compound or a prodrug thereof. The compound of the present invention has an inhibitory activity against kinase such as a vascular endothelial growth factor receptor (VEGFR) and the like, and is useful as an agent for the prophylaxis or treatment of cancer and the like.

  本发明涉及一种化合物，其表示为以下式子： 其中，A是苯环，可选地具有取代基，R1、R2a和R3分别是氢原子、可选地具有取代基的碳氢基团或可选地具有取代基的杂环基团，当R1和R2a通过X形成环时，R1和R2a可以是一个键或可选地具有取代基的双价C1-5非环烃基团，X是键、氧原子、可选地氧化的硫原子或可选地具有取代基的亚胺基团，前提是R1、R2a和X不同时为键，或其盐，以及一种抑制激酶（磷酸化酶）的药剂，其含有该化合物或其前药。 本发明的化合物具有对激酶（如血管内皮生长因子受体（VEGFR）等）的抑制活性，可用作预防或治疗癌症等疾病的药剂。
• Synthesis, antimicrobial, antimycobacterial and structure–activity relationship of substituted pyrazolo-, isoxazolo-, pyrimido- and mercaptopyrimidocyclohepta[b]indoles
  作者：Ezhumalai Yamuna、R. Ajay Kumar、Matthias Zeller、Karnam Jayarampillai Rajendra Prasad

  DOI：10.1016/j.ejmech.2011.10.046

  日期：2012.1

  A new class of heterocycles, specifically substituted pyrazolo-, isoxazolo- and pyrimidocyclohepta[b]indoles, has been prepared by condensation of substituted 7-(hydroxymethylene)-7,8,9,10-tetrahydrocyclohepta[b]indol-6(5H)-ones with hydrazine hydrate, hydroxylamine hydrochloride, phenylhydrazine, urea and thiourea, respectively. The structures of the compounds were established by IR, H-1 NMR, C-13 NMR, mass spectral analysis, X-ray diffraction, and the compounds have been screened for in vitro antimicrobial and antimycobacterial against Mycobacterium tuberculosis H37Rv (MTB). Among the compounds screened, five substances were found to have an MIC of 3.12 mu g/ml or greater against MTB. Structure-activity relationship (SAR) analyses and in silico drug relevant properties (HBD, HBA, PSA, c Log P, M.wt) confirmed that the compounds are potential lead compounds for future drug discovery studies. (C) 2011 Elsevier Masson SAS. All rights reserved.